Effect of intravitreal Bevacizumab on macular edema secondary to retinal vascular occlusion
Author(s): Dr. Nimish Kumar Singh and Vidya Bhusan Sinha
Abstract: Objective: To find out the effect of intravitreal injection of Bevacizumab on central macular thickness (CMT) and best corrected visual acuity (BCVA) in cases of retinal vascular occlusion (RVO).
Material and method: All the patients of RVO treated at our institute over a period of 1 year, with a central macular thickness of more than 250µ were included in the study. Intravitreal injection of Bevacizumab was given and the CMT and BCVA were measured after a control period of 1 month. The injection was repeated at intervals of 1.5 months if decrease in CMT was less than 30%.
Result: Out of the total 78 patients there was a significant improvement in BCVAin 58 patients. There was a significant decrease in central macular thickness in all of them.
Conclusion: Anti-VEGF agent Bevacizumab causes significant reduction in central macular thickness and improves BCVA in cases of macular edema secondary to retinal vascular occlusion.
Dr. Nimish Kumar Singh and Vidya Bhusan Sinha. Effect of intravitreal Bevacizumab on macular edema secondary to retinal vascular occlusion. International Journal of Medical Ophthalmology. 2019; 1(1): 23-25. DOI: 10.33545/26638266.2019.v1.i1a.7